



*Advancing Research. Improving Lives.™*

March 12, 2020

Dear Patient:

You are receiving this letter because you have participated in and are currently receiving treatment on NRG-GY004, **“A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.”**

The purpose of this letter is to inform you that a final analysis has just been completed. It reveals that the use of cediranib and olaparib did not extend the time until ovarian cancer relapsed compared to standard of care platinum-based therapies. Detailed information concerning the results will not become available until late May or June 2020.

However, if you are still receiving cediranib and olaparib or olaparib alone, and, after discussion of the study results with your doctor, you can choose one of the following options if you and your doctor believe one of these choices is an appropriate medical treatment for you at this time: 1) continuing on your current therapy until such time that disease progression is diagnosed. Cediranib and olaparib or olaparib alone will continue to be provided for you through the clinical trial if you choose this first option; your second option is to change to standard of care treatment or follow up as recommended by your treating physician, off study. Your physician is also receiving a letter informing him/her of this new information.

We encourage you to discuss these two options with your physician so that you can make the most appropriate decision for your care. Issues that may influence your choice include how long you have been receiving your current treatment, the status of your disease, and how you are tolerating the treatment. Once you decide, your physician will proceed accordingly.

On behalf of NRG Oncology, the three Group Chairs, and the National Cancer Institute, I want to thank you sincerely for your participation in this important clinical trial and your commitment to discovering better treatments for recurrent ovarian cancer and to wish you improved health.

Gratefully,

A handwritten signature in black ink that reads "Robert S. Mannel, MD".

Robert S. Mannel, MD  
NRG Oncology  
Group Chair